

**ELECTROSPRAYED CRISPR PLASMID DNA LOADED
ALGINATE NANOPARTICLES: PREPARATION,
CHARACTERISATION, AND GENE EDITING**

BY

BATOUL ALALLAM

**A thesis submitted in fulfillment of the requirement for the
degree of Master of Science in Pharmaceutical Science
(Pharmaceutical Technology)**

**Kulliyyah of Pharmacy
International Islamic University Malaysia**

MARCH 2021

ABSTRACT

Background: CRISPR/ Cas9 is one of the most powerful among the approaches being developed to rescue fundamental causes of gene-based inheritable diseases. Several strategies for delivering such genome editing materials have been developed, but the safety, efficacy over time, cost of production, and gene size limitations are still under debate and must be addressed to further improve applications. Sodium alginate is frequently used as the model encapsulation matrix for bioactive ingredients in the field of drug and gene delivery due to its safety. **Objective:** To encapsulate CRISPR/Cas9 plasmid DNA in alginate nanocarrier to perform genome editing. **Methodology:** alginate nanoparticles loaded with two CRISPR pDNA were fabricated using electrospray method. Both formulation and process were optimised. Chitosan-, Arabic gum- and PEG-coated CRISPR-loaded alginate nanoparticles were fabricated and characterised. CRISPR-loaded alginate nanoparticles physicochemical properties were compared to the surface-modified nanoparticle properties. The influence of surface modification of nanoparticles on their interaction with cell was studied in regard to cellular uptake, cytotoxicity, transfection efficiency, and genome editing. **Results:** Using electrospray, a nanoparticle carrier was developed to deliver CRISPR pDNA into HepG2 cells. The nanoparticles size was approximately 230 nm, with an encapsulation efficiency of 99%. Release study revealed that over one-third of the pDNA was released within the first 24 h. *In vitro* experiments conducted with HepG2 cells demonstrated that after 48 h of treatment with the CRISPR-loaded alginate nanoparticles, the particles were not toxic. CRISPR-loaded alginate nanoparticles mediated 1.5-folds more efficient transfection than a commercially available cationic liposome-based transfection reagent. However, their indel efficiency was 3.4-folds lower than the transfection reagent. The surface coating highly affected the nanoparticles physicochemical properties, consequently, their safety and efficiency in delivering the plasmid. CS CRISPR ALG NPs showed mean size and zeta potential of 377 nm and 33.67 mV, respectively. Over 90% encapsulation efficiency was achieved while protection payload from serum. The tests revealed that the nanoparticles were cytocompatible and successfully introduced the Cas9 transgene in HepG2 cells. CS CRISPR ALG NPs-transfected HepG2 was able to edit its target plasmid by introducing double-strand break (DSB) in GFP gene, 18.26-folds higher than CRISPR ALG NPs. **Conclusions:** In this work, plasmids for the CRISPR/Cas9 system were encapsulated in alginate nanoparticles and were shown to induce expression of Cas9 and perform a genome editing in HepG2 cells *in vitro*. Chitosan-coated CRISPR-loaded alginate nanoparticles revealed the best results with high plasmid protection, sustained release and high indel efficiency. These results suggest that this nanoparticle-based plasmid delivery method can be effective for future *in vivo* applications of the CRISPR/Cas9 system.

خلاصة البحث

خلفية البحث: تعد تقنية CRISPR / Cas9 من أقوى الأساليب التي يتم تطويرها لتخليص الأسباب الأساسية للأمراض الوراثية الجينية. تم تطوير العديد من الاستراتيجيات لايصال مواد التعديل الجيني هذه ، لكن السلامة والفعالية بمرور الوقت وتكلفة الإنتاج والقيود على حجم الجين لا تزال قيد المناقشة ويجب معالجتها لتحسين التطبيقات. كثيرا ما تستخدم الجينات الصوديوم كقالب تغليف نموذجي للمكونات النشطة بيولوجيا في مجال توصيل الأدوية والجينات بسبب أمنها. **هدف البحث:** لتغليف بلاسميد CRISPR / Cas9 في جسيمات نانوية من الجينات لإجراء التعديل الجيني. **طريقة البحث:** تم تصنيع الجسيمات النانوية المحملة باثنين من بلاسميدات CRISPR باستخدام طريقة النشر الكهربائي. تم تحسين كل من الصيغة و العملية. تم تصنيع و تمييز جسيمات الجينات النانوية الملبسة بالشيتوزان والصمغ العربي والبولي ايثيلين غليكول. تمت مقارنة الخصائص الفيزيائية و الكيميائية للجسيمات النانوية المحملة بـ CRISPR مع خصائص الجسيمات النانوية المعدلة السطح. تمت دراسة تأثير تعديل سطح الجسيمات النانوية على تفاعلها مع الخلية فيما يتعلق بالقبض الخلوي والسمية الخلوية وكفاءة التعديل والتعديل الجيني. **النتائج:** باستخدام النشر الكهربائي ، تم تطوير حامل جسيمات نانوية لتوصيل بلاسميدات CRISPR إلى خلايا HepG2. كان حجم الجسيمات النانوية حوالي 230 نانومتر ، بكفاءة تغليف 99%. كشفت دراسة التحرر أن أكثر من ثلث الدنا تم إطلاقه خلال الـ 24 ساعة الأولى. أظهرت التجارب المخبرية التي أجريت على خلايا HepG2 أنه بعد 48 ساعة من العلاج بجزيئات الجينات النانوية المحملة بـ CRISPR ، لم تكن الجسيمات سامة. توسطت جزيئات الجينات النانوية المحملة بـ CRISPR تعديداً أكثر كفاءة بـ 1.5 مرة من كاشف التعديداً الشحمي الموجب المتاح تجارياً. على أية حال ، كانت كفاءتهم للتعديل الجيني أقل بمقدار 3.4 أضعاف من كاشف التعديداً. أثر تلبس السطح بشكل كبير على الخصائص الفيزيائية و الكيميائية للجسيمات النانوية ، وبالتالي على سلامتها وكفاءتها في توصيل البلاسميد. أظهر جسيمات الجينات النانوية الملبسة بالشيتوزان حجم وسطي و قيمة زيتا 377 نانومتر و 33.67 مللي فولت ، على التوالي. تم تحقيق أكثر من 90% من كفاءة التغليف بالإضافة لحماية الحمولة من المصل. كشفت الاختبارات أن الجسيمات النانوية متوافقة مع الخلايا ونجحت في إدخال الجين المعدل Cas9 إلى خلايا HepG2. كان خلايا HepG2 الحاوية على جسيمات الجينات النانوية الملبسة بالشيتوزان قادرة على تعديل البلاسميد المستهدف من خلال إدخال كسر مزدوج الجديدة (DSB) في جين GFP ، أعلى بمقدار 18.26 ضعفاً من جسيمات الجينات النانوية. **الخلاصة:** في هذا العمل ، تم تغليف البلاسميدات لنظام CRISPR / Cas9 في جسيمات الجينات نانوية وتبين أنها تحفز التعبير عن Cas9 وتقوم بتحرير الجينوم في خلايا HepG2 في المختبر. كشفت جسيمات الجينات النانوية الملبسة بالشيتوزان و المحملة بـ CRISPR أفضل النتائج مع حماية عالية للبلاسميد ، وإطلاق مستمر وكفاءة عالية للتعديل الجيني. تشير هذه النتائج إلى أن طريقة توصيل البلاسميد القائمة على الجسيمات النانوية يمكن أن تكون فعالة للتطبيقات المستقبلية في الجسم الحي لنظام CRISPR / Cas9.

APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Science (Pharmaceutical Technology).

.....
Abd Almonem Doolaanea
Supervisor

.....
Muhammad Taher Bakhtiar
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Science (Pharmaceutical Technology).

.....
Izzat Fahimuddin Bin Mohamed
Suffian
Internal Examiner

.....
Mohd Hanif Bin Zulfakar
External Examiner

This thesis was submitted to the Department of Pharmaceutical Technology and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Muhammad Taher Bakhtiar
Head, Department of
Pharmaceutical Technology

This thesis was submitted to the Kulliyah of Pharmacy and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Che Suraya Hj. Mohd. Zin
Dean, Kulliyah of Pharmacy

DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Batoul Alallam

Signature

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**ELECTROSPRAYED CRISPR PLASMID DNA LOADED
ALGINATE NANOPARTICLES: PREPARATION,
CHARACTERIZATION, AND GENE EDITING**

I declare that the copyright holder of this thesis are jointly owned by the student and IIUM.

Copyright © 2021 by Batoul Alallam and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purpose.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Batoul Alallam

.....
Signature

.....
Date

*“If I were to have kids someday, this is for them. I want them to realise that once,
their mum had a dream like they do”*

ACKNOWLEDGEMENTS

All glory is due to Allah, the Almighty, whose Grace and Mercies have been with me throughout the duration of my programme. My heartfelt gratitude goes to those who provided me with their valuable time and endless support to complete this project. I would love to extend my appreciation to all the members of my dissertation committee.

My deep gratitude goes first to my advisor, Dr. Abd Almonem Doolaanea for giving me the opportunity to do research in his lab and teaching me how to design and carry out experiments independently. His ability to always recognise the positive side of any situation allowed me to have confidence in my work and encouraged me to stay motivated. This helped a lot in my research as things do not always go as expected. I hope to repay his gratitude towards me and show him how much I learned during the time spent in his lab. I look forward to our collaboration in the future. Very politely, I am grateful to Prof. Mohd Taher for his continued support and cooperation throughout my study.

I would also like to show appreciation to Dr. Izzat Suffian and Dr. Mohd Hanif Bin Zulfakar for their insightful suggestions and discussion during the progress of this work that has made me a better researcher. I would like to thank DDPG, Pharmaceutical Technology Department, CREAM officer, and lab assistant for their patience, and guidance.

All of this work would not have been possible without friends. I would like to thank my great friends May Kyaw Oo, Hazan Haryanti Abdul Halim, Alaa Bazerbashi, and Lujain Almoazen. I will never forget the great times I had during our gatherings, chit-chatting during group lunches, sipping coffee, or even fighting for nothing. I am looking forward to reading about your work in the big journals later!

Most importantly, my family. The love and support of them have been essential in my success. I love you Mama, Papa, Lina, and Mohammad, every happiness is incomplete without you.

Lastly, very special thanks to my dear uncle Mosa Alalam for always being by my side and ready to hear me. You made the years of my master's studies so complete and enriching. I could not have made it through without you. No acknowledgment is sufficient to express my gratitude to the support I have been receiving from you.

TABLE OF CONTENTS

Abstract	II
Abstract Arabic	III
Approval Page.....	IV
Declaration	V
Acknowledgements.....	VIII
List of Tables	XIII
List of Figures	XIV
List of Equations	XIX
CHAPTER ONE : INTRODUCTION.....	1
1.1 Research Background	1
1.2 Problem Statement	2
1.3 Research Aim And Objectives.....	3
1.4 Research Hypothesis	4
1.5 Research Questions	4
1.6 Significance Of The Study	4
1.7 Study Design	5
CHAPTER TWO : LITERATURE REVIEW	6
2.1 Genome Editing	6
2.2 Crispr/Cas Gene Editing System	6
2.2.1 Discovery Of Crispr/Cas9 System	6
2.2.2 The Principal Of Crispr/Cas System	7
2.3 Crispr/Cas9 Delivery System.....	10
2.3.1 Genetic Payload.....	10
2.3.1.1 Delivering Crispr/Cas9 In Dna Form	10
2.3.2 Delivery Vehicle	11
2.3.2.1 Viral Vectors	11
2.3.2.2 Non-Viral Carriers.....	11
2.3.2.2.1 Physical Delivery Methods	12
2.3.2.2.2 Chemical Delivery Methods.....	13
2.4 Sodium Alginate (Alg).....	16
2.4.1 Mechanism Of Gelation	18
2.4.1.1 External Gelation.....	19
2.4.1.2 Internal Gelation.....	19
2.4.1.3 Inverse Gelation	20
2.4.2 Calcium Alginate Particles.....	21
2.4.3 Calcium Alginate Nanospheres Preparation Methodologies	25
2.5 Preparation Of Nanoparticles Using Electrospray	26
2.5.1 Basic Setup Of Electrospray	26
2.5.2 Advantages Of Electrospray Technique.....	29
2.5.3 The Principle Of The Technique	30
2.5.4 Criteria For Ehda.....	32
2.5.5 Electrosprayed Alginate Nanoparticles	35
2.6 Barriers To Non-Viral Gene Delivery	37

2.6.1	Carrier Development In The Test Tube	38
2.6.2	During Transport To The Target Cell.	38
2.6.3	Uptake By The Target Cell	39
2.6.4	Endosomal Escape.....	39
2.6.5	Stability In Cytoplasm.....	40
2.7	Surface Modification For Improve The Intracellular Delivery Efficiency	40
2.7.1	Chitosan (Cs).....	40
2.7.2	Arabic Gum (Ga).....	42
2.7.3	Polyethylene Glycol (Peg)	43

CHAPTER THREE : PREPARATION, OPTIMISATION AND CHARACTERISATION OF CRISPR PLASMID DNA LOADED ALGINATE NANOPARTICLES..... 45

3.1	Introduction.....	45
3.2	Materials And Methods.....	47
3.2.1	Materials.....	47
3.2.2	Amplification Of Crispr Pdna	48
3.2.3	Encapsulation Of Crispr Pdna In Alg Nps	49
3.2.3.1	Characterisation Of Alginate Solutions.....	49
3.2.3.2	Selection Crispr Pdna/ Alg Ratio	49
3.2.3.3	Optimisation Of Process Variables	50
3.2.4	Characterisation Of Optimised Crispr Alg Nps	53
3.2.4.1	Particle Size And Zeta Potential Analysis.....	53
3.2.4.2	Surface Morphology.....	53
3.2.4.3	Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (Atr-Ftir)	53
3.2.4.4	Encapsulation Efficiency (Ee).....	54
3.2.4.5	Pdna Integrity Post Encapsulation	54
3.2.4.6	Pdna Serum Stability	55
3.2.4.7	In Vitro Release Profile.....	55
3.2.5	Statistical Analysis	56
3.3	Results And Discussion	56
3.3.1	Amplification Of Crispr Pdna	56
3.3.2	Optimisation Of Crispr Alg Nps	57
3.3.2.1	Characterisation Of Alginate Solutions.....	57
3.3.2.2	Selection Crispr Pdna/ Alg Ratio	62
3.3.2.3	Optimisation Of Process Variables	63
3.3.2.3.1	The Effect Of Applied Voltage On Particles Size.....	65
3.3.2.3.2	The Effect Of Flow Rate On Particles Size.....	66
3.3.3	Characterisation Of Crispr Alg Nps	68
3.3.3.1	Particle Size And Zeta Potential Analysis.....	68
3.3.3.2	Surface Morphology.....	69
3.3.3.3	Atr-Ftir	71
3.3.3.4	Encapsulation Efficiency.....	74
3.3.3.5	Evaluation Of Pdna Integrity Post-Encapsulation.....	75
3.3.3.6	Pdna Serum Stability	76
3.3.3.7	In Vitro Release Profile.....	77
3.4	Conclusion	79

CHAPTER FOUR : DETERMINATION OF PHYSICOCHEMICAL PROPERTIES OF UNCOATED AND COATED ALGINATE NANOPARTICLES LOADED WITH CRISPR PLASMID DNA 80

4.1	Introduction	80
4.2	Materials And Method	81
4.2.1	Materials	81
4.2.2	Preparation Of Coating Solutions	82
4.2.3	Preparation Of Coated Crispr Alg Nps	82
4.2.4	Optimisation Of Coating Solutions Concentration And Mw	83
4.2.5	Characterisation Of Crispr Alg Nps Coating Efficiency	83
4.2.5.1	Particle Size And Zeta Potential Analysis	83
4.2.5.2	Surface Morphology	83
4.2.5.3	Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (Atr-Ftir)	84
4.2.6	Characterisation Of Optimised Coated Crispr Alg Nps	84
4.2.6.1	Encapsulation Efficiency	84
4.2.6.2	Pdna Integrity After Encapsulation	84
4.2.6.3	Pdna Serum Stability	84
4.2.6.4	In Vitro Release Profile	85
4.2.7	Statistical Analysis	85
4.3	Results And Discussion	85
4.3.1	Optimisation Of Coating Solution Concentration And Mw	85
4.3.2	Characterisation Of Crispr Alg Nps Coating Efficiency	93
4.3.2.1	Particle Size And Zeta Potential Analysis	93
4.3.2.2	Surface Morphology	98
4.3.2.3	Atr-Ftir	99
4.3.3	Characterisation Of Optimised Coated Crispr Alg Nps	101
4.3.3.1	Encapsulation Efficiency	101
4.3.3.2	Pdna Integrity Post-Encapsulation	102
4.3.3.3	Pdna Serum Stability	102
4.3.3.4	In Vitro Release Profile	105
4.4	Conclusion	108

CHAPTER FIVE : IMPACT OF SURFACE FUNCTIONALISATION OF ALGINATE NANOPARTICLES LOADED WITH CRISPR PLASMID DNA ON THEIR *IN VITRO* CELLULAR UPTAKE, CYTOTOXICITY, TRANSFECTION, AND GENOME EDITING EFFICIENCY 110

5.1	Introduction	110
5.2	Materials And Method	111
5.2.1	Materials	111
5.2.2	Cell Culture	111
5.2.3	Uncoated And Coated Crispr Alg Nps Preparation	111
5.2.4	Cellular Uptake	112
5.2.5	Cytotoxicity Study	113
5.2.5.1	Hepg2 Standard Curve	113
5.2.5.2	Nps Cytotoxicity	114
5.2.6	<i>In Vitro</i> Transfection	115
5.2.6.1	Quantification Of Transfection Efficiency	115
5.2.7	Confirmation Of Gene Editing Using Nps	116

5.2.8	Statistical Analysis	117
5.3	Results And Discussion	118
5.3.1	Cellular Uptake	118
5.3.1.1	Effects Of Nps Concentration And Incubation Time On Cellular Uptake Of Uncoated And Coated Crispr Alg Nps	119
5.3.1.2	Effect Of Surface Coating On Cellular Uptake Of Crispr Alg Nps	128
5.3.2	Cytotoxicity Study.....	133
5.3.2.1	Hepg2 Standard Curve	133
5.3.2.2	Crispr Alg Nps Cytotoxicity	133
5.3.2.2.1	Effect Of Surface Coating On Nps Toxicity	137
5.3.3	Quantification Of The Transfection Efficiency	142
5.3.3.1	Optimisation Of Transfection Reagent	142
5.3.3.2	Transfection Efficiency Of Crispr Alg Nps	143
5.3.3.3	Effect Of Surface Coating On Transfection Efficiency Of Crispr Alg Nps	148
5.3.4	Confirmation Of Gene Editing Using Nps.....	155
5.3.4.1	Effect Of Surface Coating On Genome Editing Efficiency	158
5.4	Conclusion	160
CHAPTER SIX : GENERAL DISCUSSION AND CONCLUSION		161
6.1	General Conclusion.....	161
6.2	Research Limitation	165
6.3	Future Work And Suggestions.....	165
6.3.1	Proposed Application Of Electrosprayed Chitosan Coated Alginate Nanoparticles For Viral Infection Prevention	166
REFERENCES.....		168
Appendix I: Institutional Biosafety & Biosecurity Assessment Forms.....		193
Appendix II: Research Achievement.....		201
Appendix III: SpCas9-2a-miRFP670 Vector Gene Map.....		203
Appendix IV: GRNA_GFP-T2 Vector Gene Map.....		204
Appendix V: PcDNA3-EEGF Vector Gene Map		205
Appendix VI: Proofreading Aknowldgment Letter.....		206

LIST OF TABLES

Table 3.1	Experimental runs, and variables of the 3 ² full factorial design for the CRISPR ALG NPs	51
Table 3.2	Composition of ALG solutions and their physicochemical properties	59
Table 3.3	The encapsulation efficiencies of CRISPR ALG NPs with different pDNA to ALG weight ratio	63
Table 3.4	Comparison of particle size, PDI and zeta potential of CRISPR ALG NPs and blank ALG NPs	69
Table 3.5	CRISPR ALG NPs size and PDI obtained from TEM	70
Table 4.1	Summary of the composition of each coating solution with different types of polymer (CS, PEG and GA), MW (low, medium and high) and concentration (0.1, 0.3 and 0.6% w/v) and their NPs characterisation results, zeta potential and EE (n=3)	86
Table 4.2	The particle size, particle size distribution, zeta potential, and encapsulation efficiencies for CRISPR ALG NPs, CS CRISPR ALG NPs, GA CRISPR ALG NPs, and PEG CRISPR ALG NPs	97
Table 5.1	The particle size of unlabelled or coumarin-6 labelled CRISPR ALG NPs (with and without coating)	118
Table 6.1	Summary of the surface coating effect on physicochemical and biological properties of CRISPR-loaded alginate nanoparticles	164

LIST OF FIGURES

Figure 2.1	The principle of CRISPR/Cas9-mediated gene disruption	9
Figure 2.2	Alginate chemical structure	17
Figure 2.3	Egg-box model of alginate gelation	19
Figure 2.4	Electrospray apparatus basic set up	27
Figure 2.5	Double parallel-capillaries coaxial nozzle	28
Figure 2.6	Triple-capillaries coaxial nozzle	28
Figure 2.7	Multiplexed electro spraying setup with several electro spray sources operating in parallel and an extractor	29
Figure 2.8	Controlling forces for cone jet formation as well as the breakup of charged jet in electro spraying process	31
Figure 2.9	The electro spray modes change as the voltage increases	33
Figure 2.10	Nanoparticles preparation using electro spray technique	36
Figure 2.11	Barriers involved in DNA delivery for successful transfection	37
Figure 2.12	Chemical structure of (A) chitin, and (B) chitosan	42
Figure 2.13	Polyethylene glycol chemical structure	44
Figure 3.1	Experimental setup of electro spray fabrication of calcium alginate nanoparticles in cone jet mode	52
Figure 3.2	pDNA integrity after extraction	57
Figure 3.3	Scheme plot of shear stress vs shear rate of alginate solutions	58
Figure 3.4	Camera image showing the spray mode by different alginate solutions	62
Figure 3.5	Mean metabolic activities (mean \pm SD; n=3) of Hep G2 cells after treatment with CRISPR ALG NPs at concentration equivalent to 1 μ g pDNA	63
Figure 3.6	The main effect plot of flow rate and applied voltage on the particle size	67

Figure 3.7	The interaction effect plot of flow rate and applied voltage on particle size	68
Figure 3.8	The particle size distribution by intensity for optimised blank ALG NPs and CRISPR ALG NPs	69
Figure 3.9	TEM image for CRISPR ALG NPs	71
Figure 3.10	ATR-FTIR spectra of sodium alginate, Tween 20 calcium chloride, CRISPR plasmids, blank ALG NPs, CRISPR ALG NPs and <i>in silico</i> CRISPR ALG NPs	74
Figure 3.11	Integrity of CRISPR pDNA after encapsulation, Stability of CRISPR ALG NPs in the presence of serum after 1 and 24 h incubation, and Stability of released CRISPR pDNA from ALG NPs	76
Figure 3.12	Cumulative release of CRISPR pDNA from CRISPR ALG NPs (mean \pm SD; n=3) in pH 7.4 PBS	78
Figure 4.1	The main effect of chitosan molecular weight and concentration on particles zeta potential	88
Figure 4.2	The interaction effect of chitosan molecular weight and concentration on particles zeta potential	88
Figure 4.3	The main effect of chitosan molecular weight and concentration on particles encapsulation efficiency	89
Figure 4.4	The interaction effect of chitosan molecular weight and concentration on particles encapsulation efficiency	90
Figure 4.5	The main effect of PEG molecular weight and concentration on particles zeta potential	91
Figure 4.6	The interaction effect of PEG molecular weight and concentration on particles zeta potential	91
Figure 4.7	The main effect of PEG molecular weight and concentration on particles encapsulation efficiency	92
Figure 4.8	The interaction effect of PEG molecular weight and concentration on particles encapsulation efficiency	92
Figure 4.9	TEM image of (A) CS CRISPR ALG NPs (B) GA CRISPR ALG NPs and (C) PEG CRISPR ALG NP	99
Figure 4.10	ATR-FTIR spectra of CS, GA, PEG, CRISPR ALG NPs, CS CRISPR ALG NPs, GA CRISPR ALG NPs and PEG CRISPR ALG NPs	101

Figure 4.11	pDNA integrity after extraction from coated CRISPR ALG NPs	104
Figure 4.12	Release profile of uncoated and coated CRISPR ALG NPs over 8 days	107
Figure 5.1	Coumarin-6 CRISPR alginate solution	112
Figure 5.2	The mean fluorescence intensity of coumarin-6 labelled CRISPR ALG NPs at different incubation times, (mean \pm SD; n=3)	119
Figure 5.3	Uptake efficiency of coumarin-6 labelled CRISPR ALG NPs at different incubation times, (mean \pm SD; n=3)	120
Figure 5.4	The cellular uptake of coumarin-6 labelled CRISPR ALG NPs in HepG2 cell at various times and concentration at 37 °C	120
Figure 5.5	The mean fluorescence intensity of coumarin-6 labelled CS CRISPR ALG NPs at different incubation times, (mean \pm SD; n=3)	121
Figure 5.6	Uptake efficiency of coumarin-6 labelled CS CRISPR ALG NPs at different incubation times, (mean \pm SD; n=3)	122
Figure 5.7	The cellular uptake of coumarin-6 labelled CS CRISPR ALG NPs in HepG2 cell at various times and concentration at 37°C	123
Figure 5.8	The mean fluorescence intensity of coumarin-6 labelled GA CRISPR ALG NPs at different incubation times, (mean \pm SD; n=3)	124
Figure 5.9	Uptake efficiency of coumarin-6 labelled GA CRISPR ALG NPs at different incubation times, (mean \pm SD; n=3)	124
Figure 5.10	The cellular uptake of coumarin-6 labelled GA CRISPR ALG NPs in HepG2 cell at various times and concentration at 37°C	125
Figure 5.11	The mean fluorescence intensity of coumarin-6 labelled PEG CRISPR ALG NPs at different incubation times, (mean \pm SD; n=3)	126
Figure 5.12	Uptake efficiency of coumarin-6 labelled PEG CRISPR ALG NPs at different incubation times, (mean \pm SD; n=3)	127
Figure 5.13	The cellular uptake of coumarin-6 labelled PEG CRISPR ALG NPs in HepG2 cell at various times and concentration at 37°C	127

Figure 5.14	Mean fluorescence intensity of coumarin-6 labelled uncoated and coated coumarin-6 labelled CRISPR ALG NPs with concentration of 125 $\mu\text{g}/\text{mL}$, 2 h incubation time in HepG2 cells at 37°C, and (B) HepG2 uptake efficiency of uncoated and coated coumarin-6 labelled CRISPR ALG NPs with concentration of 125 $\mu\text{g}/\text{mL}$, 2 h incubation time and 37°C	129
Figure 5.15	The cellular uptake of coumarin-6 labelled CRISPR ALG NPs (with and without coating) in HepG2 cells at concentration 125 $\mu\text{g}/\text{mL}$ at 37°C for 2 h	132
Figure 5.16	MTT standard curve for HepG2 cells after 48 h incubation	133
Figure 5.17	Relative metabolic activity of Hep G2 cells 48 h post-treatment with CRISPR ALG NPs (mean \pm SD; n=3). pDNA:NP ratio 1:10 w/w	135
Figure 5.18	HepG2 morphology 48 h post-treatment with: (A) pDNA: NanoJuice TR (1 μg :2.5 μL), (B) naked pDNA at concentration 1 μg , (C) CRISPR ALG NPs at 100 $\mu\text{g}/\text{mL}$ concentration, (D) CS CRISPR ALG NPs at 100 $\mu\text{g}/\text{mL}$ concentration, (E) GA CRISPR ALG NPs at 100 $\mu\text{g}/\text{mL}$ concentration, and (F) PEG CRISPR ALG NPs at 100 $\mu\text{g}/\text{mL}$ concentration	136
Figure 5.19	Relative metabolic activity of Hep G2 cells 48 h post-treatment with CS CRISPR ALG NPs (mean \pm SD; n=3). pDNA:NP ratio 1:10 w/w	139
Figure 5.20	HepG2 cells treated with high zeta potential CS CRISPR ALG NPs	139
Figure 5.21	Relative metabolic activity of Hep G2 cells 48 h post-treatment with GA CRISPR ALG NPs (mean \pm SD; n=3). pDNA:NP ratio 1:10 w/w	140
Figure 5.22	Relative metabolic activity of Hep G2 cells 48 h post-treatment with PEG CRISPR ALG NPs (mean \pm SD; n=3). pDNA: NP ratio 1:10 w/w	141
Figure 5.23	Relative metabolic activity of Hep G2 cells 48 h post-treatment with uncoated and coated CRISPR ALG NPs (mean \pm SD; n=3). pDNA: NP ratio 1:10 w/w	142
Figure 5.24	RFP fluorescence in transfected HepG2 cells 48 and 72 h after transfection of RFP-expressing CRISPR plasmid	146
Figure 5.25	Transfection efficiencies by different reagents in HepG2 cells	147
Figure 5.26	Mean red fluorescence intensity expression by different reagents in HepG2 cells 48 h post-transfection	147

Figure 5.27	RFP fluorescence in transfected HepG2 cells 48 h after transfection of RFP-expressing CRISPR plasmid	151
Figure 5.28	Transfection efficiencies by different reagents in HepG2 cells	152
Figure 5.29	RFP fluorescence in transfected HepG2 cells 48 h post-transfection of RFP-expressing CRISPR plasmid	153
Figure 5.30	Transfection efficiencies by different reagents in HepG2 cells	154
Figure 5.31	Relative fold expression of RFP expression by different reagents in HepG2 cells 48 h post-transfection	155
Figure 5.32	Representative scheme for genome editing using CRISPR/Cas9 plasmids	156
Figure 5.33	Gel electrophoresis Analysis of <i>in vitro</i> ability of CRISPR pDNA delivered by uncoated and coated alginate nanoparticles to induce DSB of targeted DNA	157

LIST OF EQUATIONS

Equation 2.1	31
Equation 3.1	54
Equation 3.2	65
Equation 5.1	116

LIST OF ABBREVIATIONS

AGE	Agarose gel electrophoresis
ALG	Alginate
ANOVA	Analysis of variance
ATR-FTIR	Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy
bp	Base pair
Cas	CRISPR Associated protein
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats
CRISPR ALG NPs	Alginate nanoparticles loaded with two CRISPR plasmid DNA
crRNA	CRISPR RNA
CS	Chitosan
CS CRISPR ALG NPs	Alginate nanoparticles loaded with two CRISPR plasmid DNA and coated with chitosan
DHDA	Electrohydrodynamic atomisation
Di 50	Median diameter
DMEM	Dulbecco's Modified Eagle Medium
DMSO	Dimethyl sulfoxide
DOTAP	1,2-dioleoyl-3-trimethylammoniumpropane
DSB	Double Strand Break
<i>E coli</i>	<i>Escherichia coli</i>
EE	Encapsulation Efficiency
FBS	Fetal bovine serum
G	α -L-guluronic acid
GA	Arabic gum
GA CRISPR ALG NPs	Alginate nanoparticles loaded with two CRISPR plasmid DNA and coated with arabic gum
GFP	Green Fluorescent Protein
gRNA	Guide Ribonucleic Acid
h	Hour
HepG2	Hepatocellular carcinoma
<i>In vitro</i>	Research or work is done in the glass
<i>In vivo</i>	Research or work is done with or within an entire, living organism.
INDELS	Insertions/Deletions
kb	kilobases
kDa	Kilo Dalton
Kg	Kilo gram
kV	Kilovolt
LB	Luria-Bertani
M	β -D-mannuronic acid
m ³	Meter cube
min	Minute
mPa.	Mili pascal
mRNA	Massenger Ribonucleic Acid
ms	Mili second

MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MW	Molecular weight
N	Newton
NHEJ	Non-Homologous End Joining
nm	Nanometer
NPs	Nanoparticles
o/w	Oil-in-water
PAM	Protospacer Adjacent Motif
PBS	Phosphate buffer saline
PCR	Polymerase Chain Reaction
PDI	Poly dispersity index
pDNA	Plasmid DNA
PEG	Polyethylene glycol
PEG CRISPR ALG NPs	Alginate nanoparticles loaded with two CRISPR plasmid DNA and coated with polyethylene glycol
PLGA	Poly(lactic-co-glycolic acid)
RFP	Red Fluorescent Protein
RNA	Ribonucleic Acid
s	Second
S	Solution
<i>Sa</i> Cas9	Cas9 derived from <i>Staphylococcus aureus</i>
SD	Standard Deviation
<i>Sp</i> Cas9	Cas9 derived from <i>Streptococcus pyrogenes</i>
T7EI	T7 endonuclease I
TAE	Tris acetate edetate
TEM	Transmission Electron Microscope
TR	Transfection Reagent
tracerRNA	Trans CRISPR RNA
V	Volt
v/v	The amount by volume of a solid substance dissolved in a known amount (by volume) of liquid
w/o	Water-in-oil
w/v	The amount by weight of a solid substance dissolved in a known amount (by volume) of liquid

CHAPTER ONE

INTRODUCTION

1.1 RESEARCH BACKGROUND

The emergence of the clustered regulatory interspaced short palindromic repeat (CRISPR)/CRISPR associated protein (Cas) genome editing system has brought much excitement to the field of gene therapy and the larger scientific community. The application of CRISPR-based technologies seems to be endless, ranging from increasing crop resistance to curing genetic diseases previously considered untreatable, providing a flexible approach to high-fidelity gene editing. Nevertheless, in order for CRISPR-based therapies to be translated to *in vivo* application, there is an urgent need to develop optimised vectors for their delivery. The delivery vector is a crucial determinant of the therapeutic efficacy of gene editing and should be designed to accommodate various factors including the form of the payload, and the physiological environment. The large majority of CRISPR plasmid therapy has been based on the use of viral vectors (Ding *et al.*, 2014; Ran *et al.*, 2015; Kaminski *et al.*, 2016; Long *et al.*, 2016; Nelson *et al.*, 2016). However, several drawbacks have been associated with their delivery, among these: immunogenicity (Wang *et al.*, 2015), carcinogenesis (Donahue *et al.*, 1992), and limited packaging size (Ran *et al.*, 2015). Non-viral gene delivery systems were developed with potential to overcome these limitations; nevertheless, nanoparticle delivery is still challenged with difficulty in scale-up manufacturing and low gene delivery efficiency compared to viral delivery. Recently, biomaterials have become an attractive option for the delivery of Cas9 due to their tunability, biocompatibility and increasing efficacy at drug delivery. Biomaterials offer a unique

solution for creating tailored vectors to meet the demands of various applications that cannot be easily met by other delivery methods. In this study, we optimise a delivery carrier for CRISPR/Cas9 system in its plasmid form. Therefore, two CRISPR plasmid DNA were encapsulated into alginate nanoparticles using electrospray method. The optimisation of the formulation and process variables were done using a statistical approach. The nanoparticles were characterised in terms of their physicochemical characteristics. In addition, functionalisation of the surface of CRISPR plasmid DNA-loaded alginate nanoparticles (CRISPR ALG NPs) was done using three polymers (chitosan, Arabic gum, and polyethylene glycol) to understand their roles in carrier properties. Finally, the influence of surface functionalisation in the safety and efficiency of the carrier in CRISPR/Cas9 delivery was evaluated.

This project will help to understand the relationship between the nanoparticle formulation and the efficacy of gene editing and ultimately guide the field in designing new delivery systems that can lead to develop the best formulation serves as a carrier for the clinical applications of CRISPR/Cas9.

1.2 PROBLEM STATEMENT

In recent decades, gene editing CRISPR/Cas systems have become a platform in biomedical research due to its high potential for treating viral infections (Schwank *et al.*, 2013). Many benefits were utilised from CRISPR/Cas systems *in vitro*. However, the delivery system remains the main challenge for robust implementation of CRISPR system *in vivo*. Multiple methods are seen for delivering *in vitro*, which are usually not compatible or unsafe for *in vivo* use (Wang *et al.*, 2017). Polymeric nanoparticles are alternative delivery vector that can be prepared from biocompatible materials. Alginate nanoparticles appeared to be an excellent candidate' for polymeric carrier to deliver

CRISPR plasmids. Nucleic acid and protein have been successfully encapsulated in alginate micro and nanoparticle (You & Peng, 2005; Tahtat *et al.*, 2013; Mukhopadhyay *et al.*, 2015; Zhang *et al.*, 2016). However, to translate the gene editing into a therapeutic benefit, the maximum gene editing efficacy should be attempted. Up until this day, there is still a lack of research that investigates the effect of the nanoparticle properties onto their efficacy of the gene editing using CRISPR system (Tao *et al.*, 2019).

1.3 RESEARCH AIM AND OBJECTIVES

This research aims to develop and optimise a carrier for two CRISPR plasmid DNA by an easy and applicable method with special emphasis on safety and efficiency of the carrier. Based on this aim, the objectives of the proposed project are summarised as follows:

- i. To optimise and characterise alginate nanoparticles to encapsulate CRISPR plasmid DNA using electrospray technique.
- ii. To optimise the surface coating of CRISPR-loaded alginate nanoparticles *via* applying different coating molecule
- iii. To investigate the effect of surface coating on the nanoparticle's physicochemical properties.
- iv. To evaluate *in vitro* cellular uptake, cytotoxicity, transfection efficiency, and genome editing efficiency of the CRISPR-loaded alginate nanoparticles.
- v. To investigate how different surface coating of the nanoparticles affects their genome editing efficiency.